Novartis to Fund US Commercialization of CML Companion Dx on Cepheid's GeneXpert System

The deal is expected to aid physicians in managing Ph+ CML patients treated with Novartis' Gleevec, and allows Cepheid to expand the test menu for its PCR-based GeneXpert platform, potentially driving additional sales of the system.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories